A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00853385
First received: February 27, 2009
Last updated: January 10, 2013
Last verified: January 2013
  Purpose

This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also included.


Condition Intervention Phase
Rheumatoid Arthritis
Drug: CP 690,550
Drug: CP-690,550
Other: Placebo
Biological: Biologic TNFi
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 [ Time Frame: Month 6 ] [ Designated as safety issue: No ]
    ACR20 response: greater than or equal to (>=) 20% improvement in tender joint count (TJC); >= 20% improvement in swollen joint count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.

  • Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 3 analysis.

  • Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6 [ Time Frame: Month 6 ] [ Designated as safety issue: No ]
    DAS28-4 (ESR) calculated from SJC and TJC using 28-joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (<=) 3.2 implied low disease activity and > 3.2 to 5.1 implied moderate to high disease activity, and < 2.6 = remission. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.


Secondary Outcome Measures:
  • Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 1 and 3 [ Time Frame: Month 1, 3 ] [ Designated as safety issue: No ]
    ACR20 response: >=20% improvement in TJC; >= 20% improvement in SJC; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

  • Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

  • Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 1, 3 and 6 [ Time Frame: Month 1, 3, 6 ] [ Designated as safety issue: No ]
    ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

  • Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

  • Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 1, 3 and 6 [ Time Frame: Month 1, 3, 6 ] [ Designated as safety issue: No ]
    ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

  • Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

  • Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

  • Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

  • Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

  • Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

  • Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) [ Time Frame: Baseline, Month 1, 3, 6, 9, 12 ] [ Designated as safety issue: No ]
    DAS28-4 [CRP] calculated from SJC and TJC using 28 joint count, CRP (mg/L) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

  • Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR]) [ Time Frame: Baseline, Month 1, 3, 6, 9, 12 ] [ Designated as safety issue: No ]
    DAS28-3 (ESR) was calculated from SJC and TJC using 28 joint count and ESR (mm/hour). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

  • Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 1, 3 and 6 [ Time Frame: Month 1, 3, 6 ] [ Designated as safety issue: No ]
    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.

  • Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.

  • Patient Assessment of Arthritis Pain at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

  • Patient Assessment of Arthritis Pain at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.

  • Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.

  • Patient Global Assessment (PtGA) of Arthritis Pain at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.

  • Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

  • Physician Global Assessment (PGA) of Arthritis Pain at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

  • 36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.

  • 36-Item Short-Form Health Survey (SF-36) at Month 9 and 12 [ Time Frame: Month 9, 12 ] [ Designated as safety issue: No ]
    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.

  • Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

  • Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

  • Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

  • Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

  • Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

  • Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

  • Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Baseline, Month 1, 3 and 6 [ Time Frame: Baseline, Month 1, 3, 6 ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

  • Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

  • Work Limitations Questionnaire (WLQ) Score at Month 3 and 6 [ Time Frame: Month 3, 6 ] [ Designated as safety issue: No ]
    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).

  • Work Limitations Questionnaire (WLQ) Score at Baseline and Month 12 [ Time Frame: Baseline, Month 12 ] [ Designated as safety issue: No ]
    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).

  • Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6 [ Time Frame: Baseline, Month 3, 6 ] [ Designated as safety issue: No ]
    Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: any RA/non-RA related medical/non-medical (NM) practitioner visit, nursing home, hospital, surgery, emergency room (ER) treatment, diagnostic tests, over-night stay, home healthcare (HC) services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.

  • Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    RA-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, NM practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, over-night stay, home HC services, and aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.

  • Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6 [ Time Frame: Baseline, Month 3, 6 ] [ Designated as safety issue: No ]
    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

  • Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

  • Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6 [ Time Frame: Baseline, Month 3, 6 ] [ Designated as safety issue: No ]
    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

  • Number of Days as Assessed Using RA-HCRU at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

  • Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6 [ Time Frame: Baseline, Month 3, 6 ] [ Designated as safety issue: No ]
    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.

  • Number of Hours Per Day as Assessed RA-HCRU at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.

  • Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6 [ Time Frame: Baseline, Month 3, 6 ] [ Designated as safety issue: No ]
    Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.

  • Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.


Enrollment: 717
Study Start Date: May 2009
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 5mg Drug: CP 690,550
tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
Experimental: 10 mg Drug: CP-690,550
tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
Placebo Comparator: Placebo Sequence 1 Other: Placebo
placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
Placebo Comparator: Placebo Sequence 2 Other: Placebo
tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
Active Comparator: adalimumab Biological: Biologic TNFi
placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
Other Name: Humira (Adalimumab)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.
  • The patient must have had an inadequate response to methotrexate and have active disease, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) >28 mm in the local laboratory. 2. CRP >7 mg/L in the central laboratory.
  • No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
  • The patient must have been on a stable dose of 7.5 mg to 25 mg weekly of methotrexate and washed out of all other DMARDs.

Exclusion Criteria:

  • Blood dyscrasias including confirmed: 1. Hemoglobin <9 g/dL or Hematocrit <30%; 2. White blood cell count <3,000 cu.mm. Absolute neutrophil count <1,200 cu.mm; 4. Platelet count <100,000/L
  • History of any other autoimmune rheumatic disease other than Sjogren's syndrome
  • No malignancy or history of malignancy.
  • History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug
  • Patients who have failed any TNFi for either lack of efficacy or a TNFi mechanism related adverse event.
  • Patients who have previously received adalimumab therapy for any reason.
  • Patients who are contraindicated for treatment with adalimumab in accordance with the approved local label.
  • Patients meeting the New York Heart Association Class III and Class IV Congestive Heart failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00853385

  Hide Study Locations
Locations
United States, Arizona
Pfizer Investigational Site
Gilbert, Arizona, United States, 85234
Pfizer Investigational Site
Glendale, Arizona, United States, 85304
Pfizer Investigational Site
Mesa, Arizona, United States, 85202
Pfizer Investigational Site
Paradise Valley, Arizona, United States, 85253
Pfizer Investigational Site
Phoenix, Arizona, United States, 85037
United States, Arkansas
Pfizer Investigational Site
Jonesboro, Arkansas, United States, 72401
United States, California
Pfizer Investigational Site
Fair Oaks, California, United States, 95628
Pfizer Investigational Site
San Diego, California, United States, 92108
United States, Colorado
Pfizer Investigational Site
Boulder, Colorado, United States, 80304
United States, Florida
Pfizer Investigational Site
Largo, Florida, United States, 33777
Pfizer Investigational Site
Naples, Florida, United States, 34102
Pfizer Investigational Site
Palm Harbor, Florida, United States, 34684
Pfizer Investigational Site
Pinellas Park, Florida, United States, 33782
Pfizer Investigational Site
Plantation, Florida, United States, 33324
Pfizer Investigational Site
St. Petersburg, Florida, United States, 33710
Pfizer Investigational Site
Tampa, Florida, United States, 33613
United States, Georgia
Pfizer Investigational Site
Decatur, Georgia, United States, 30033
Pfizer Investigational Site
Marietta, Georgia, United States, 30060
United States, Illinois
Pfizer Investigational Site
Rockford, Illinois, United States, 61107
United States, Indiana
Pfizer Investigational Site
Evansville, Indiana, United States, 47714
United States, Kansas
Pfizer Investigational Site
Wichita, Kansas, United States, 67203
United States, Kentucky
Pfizer Investigational Site
Lexington, Kentucky, United States, 40515
Pfizer Investigational Site
Lexington, Kentucky, United States, 40504
United States, Louisiana
Pfizer Investigational Site
Baton Rouge, Louisiana, United States, 70809
United States, Massachusetts
Pfizer Investigational Site
Haverhill, Massachusetts, United States, 01830
Pfizer Investigational Site
Worcester, Massachusetts, United States, 01610
United States, Michigan
Pfizer Investigational Site
Grand Rapids, Michigan, United States, 49546
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45219
United States, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73112
United States, South Carolina
Pfizer Investigational Site
Greenville, South Carolina, United States, 29601
United States, Texas
Pfizer Investigational Site
Austin, Texas, United States, 78705
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
Houston, Texas, United States, 77034
Pfizer Investigational Site
Lubbock, Texas, United States, 79424
Pfizer Investigational Site
Mesquite, Texas, United States, 75150
United States, Washington
Pfizer Investigational Site
Seattle, Washington, United States, 98122
Pfizer Investigational Site
Seattle, Washington, United States, 98104
United States, West Virginia
Pfizer Investigational Site
Clarksburg, West Virginia, United States, 26301
Australia, New South Wales
Pfizer Investigational Site
St Leonards, New South Wales, Australia, 2065
Australia, Queensland
Pfizer Investigational Site
Cairns, Queensland, Australia, 4870
Pfizer Investigational Site
Maroochydore, Queensland, Australia, 4558
Australia, Victoria
Pfizer Investigational Site
Malvern East, Victoria, Australia, 3145
Bosnia and Herzegovina
Pfizer Investigational Site
Sarajevo, Bosnia and Herzegovina, 71000
Bulgaria
Pfizer Investigational Site
Pleven, Bulgaria, 5800
Pfizer Investigational Site
Plovdiv, Bulgaria, 4000
Pfizer Investigational Site
Plovdiv, Bulgaria, 4002
Pfizer Investigational Site
Sevlievo, Bulgaria, 5400
Pfizer Investigational Site
Sofia, Bulgaria, 1606
Pfizer Investigational Site
Sofia, Bulgaria, 1709
Canada, British Columbia
Pfizer Investigational Site
Vancouver, British Columbia, Canada, V5Z 1L7
Canada, Nova Scotia
Pfizer Investigational Site
Lunenburg, Nova Scotia, Canada, B0J 2C0
Canada, Ontario
Pfizer Investigational Site
London, Ontario, Canada, N6A 4V2
Pfizer Investigational Site
Mississauga, Ontario, Canada, L5M 2V8
Pfizer Investigational Site
Toronto, Ontario, Canada, M5T 2S8
Canada, Quebec
Pfizer Investigational Site
Trois-Rivieres, Quebec, Canada, G8Z 1Y2
Canada, Saskatchewan
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada, S7N 0W8
Canada
Pfizer Investigational Site
Quebec, Canada, G1W 4R4
Chile
Pfizer Investigational Site
Santiago, RM, Chile, 7510186
Pfizer Investigational Site
Santiago, RM, Chile, 8360156
Pfizer Investigational Site
Providencia, Santiago, RM, Chile, 7530206
Pfizer Investigational Site
Rancagua, VI Region, Chile, 2841959
Costa Rica
Pfizer Investigational Site
Cartago, Costa Rica
Pfizer Investigational Site
San Jose, Costa Rica
Pfizer Investigational Site
San Jose, Costa Rica, 00
Croatia
Pfizer Investigational Site
Osijek, Croatia, 31000
Pfizer Investigational Site
Split, Croatia, 21000
Pfizer Investigational Site
Zagreb, Croatia, 10000
Czech Republic
Pfizer Investigational Site
Brno, Czech Republic, 656 91
Pfizer Investigational Site
Brno, Czech Republic, 60200
Pfizer Investigational Site
Brno, Czech Republic, 65691
Pfizer Investigational Site
Brno - Zidenice, Czech Republic, 615 00
Pfizer Investigational Site
Hlucin, Czech Republic, 748 01
Pfizer Investigational Site
Pardubice, Czech Republic, 530 02
Pfizer Investigational Site
Praha 11, Czech Republic, 14800
Pfizer Investigational Site
Praha 11 - Chodov, Czech Republic, 148 00
Pfizer Investigational Site
Praha 2, Czech Republic, 128 50
Pfizer Investigational Site
Praha 4, Czech Republic, 140 00
Pfizer Investigational Site
Zlin, Czech Republic, 760 01
Denmark
Pfizer Investigational Site
Frederiksberg, Denmark, 2000
Pfizer Investigational Site
Randers NOE, Denmark, 8930
Dominican Republic
Pfizer Investigational Site
Santo Domingo, Dominican Republic, 00000
Finland
Pfizer Investigational Site
Hyvinkaa, Finland, 05800
Germany
Pfizer Investigational Site
Aachen, Germany, 52064
Pfizer Investigational Site
Berlin, Germany, 14059
Pfizer Investigational Site
Frankfurt am Main, Germany, 60590
Pfizer Investigational Site
Halle, Germany, 06128
Pfizer Investigational Site
Halle, Germany, 06108
Pfizer Investigational Site
Herne, Germany, 44652
Pfizer Investigational Site
Ratingen, Germany, 40882
Pfizer Investigational Site
Wuerzburg, Germany, 97080
Korea, Republic of
Pfizer Investigational Site
Daegu, Korea, Republic of, 705-718
Pfizer Investigational Site
Gwangju, Korea, Republic of, 501-757
Pfizer Investigational Site
Seoul, Korea, Republic of, 110-744
Pfizer Investigational Site
Seoul, Korea, Republic of, 133-792
Mexico
Pfizer Investigational Site
Mexico, DF, Mexico, 10700
Pfizer Investigational Site
Guadalajara, Jalisco, Mexico, 44620
Pfizer Investigational Site
Morelia, Michoacan, Mexico, 58249
Pfizer Investigational Site
San Luis Potosi, SLP, Mexico, 78240
Philippines
Pfizer Investigational Site
Lipa City, Batangas, Philippines, 4217
Pfizer Investigational Site
Angeles City, Pampanga, Philippines, 2009
Pfizer Investigational Site
Cebu City, Philippines, 6000
Poland
Pfizer Investigational Site
Bialystok, Poland, 15-337
Pfizer Investigational Site
Cieszyn, Poland, 43-400
Pfizer Investigational Site
Koscian, Poland, 64-000
Pfizer Investigational Site
Krakow, Poland, 31-501
Pfizer Investigational Site
Sopot, Poland, 81-759
Pfizer Investigational Site
Torun, Poland, 87-100
Pfizer Investigational Site
Warszawa, Poland, 02-118
Slovakia
Pfizer Investigational Site
Bratislava, Slovakia, 82606
Pfizer Investigational Site
Dunajska Streda, Slovakia, 92901
Pfizer Investigational Site
Kosice, Slovakia, 040 01
Pfizer Investigational Site
Nove Zamky, Slovakia, 94001
Pfizer Investigational Site
Povazska Dystrica, Slovakia, 017 01
Pfizer Investigational Site
Zilina, Slovakia, 010 01
Spain
Pfizer Investigational Site
Santiago de Compostela, A Coruña, Spain, 15705
Pfizer Investigational Site
Vigo, Pontevedra, Spain, 36200
Pfizer Investigational Site
A Coruña, Spain, 15006
Pfizer Investigational Site
Madrid, Spain, 28041
Pfizer Investigational Site
Sevilla, Spain, 41009
Pfizer Investigational Site
Valencia, Spain, 46026
Thailand
Pfizer Investigational Site
Rajathevee, Bangkok, Thailand, 10400
Pfizer Investigational Site
Amphoe Muang, Chiang Mai, Thailand, 50200
United Kingdom
Pfizer Investigational Site
Wirral, Merseyside, United Kingdom, CH49 5PE
Pfizer Investigational Site
Cannock, Staffs, United Kingdom, WS11 2XY
Pfizer Investigational Site
Dudley, West Midlands, United Kingdom, DY1 2HQ
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00853385     History of Changes
Other Study ID Numbers: A3921064
Study First Received: February 27, 2009
Results First Received: December 4, 2012
Last Updated: January 10, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
oral DMARD
JAK inhibitor
clinical trial

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Tofacitinib
Adalimumab
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents

ClinicalTrials.gov processed this record on September 30, 2014